Experimental antibody combo aims to boost immune attack on head and neck tumors
NCT ID NCT03690986
First seen Jul 16, 2026 · Last updated Jul 17, 2026 · Updated 1 time
Summary
This phase 1 trial tests whether adding an experimental antibody called VX15/2503 to standard immunotherapy drugs (ipilimumab or nivolumab) can help shrink head and neck cancers before surgery. The study enrolls people with early-stage (I-IVA) squamous cell carcinoma of the head and neck who have not received prior treatment. Researchers will measure changes in immune cells within tumors and blood to see if the combination improves the body's ability to fight cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- a combination of an experimental antibody (VX15/2503) with immunotherapy drugs (ipilimumab or nivolumab)
- What this could lead to
- If successful, this combination could offer a new treatment option for head and neck cancer patients who have not had prior therapy.
- What could go wrong
- This is an early phase 1 trial with only 35 participants, so results may not apply broadly. The combination may cause significant side effects or fail to improve outcomes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Emory University Hospital Midtown
Atlanta, Georgia, 30308, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Scientists hunt for blood markers to unmask hidden aggressive tumors
- Liver damage study in head and neck cancer abandoned after just 2 patients
- New antibody drug takes aim at Hard-to-Treat cancers
- MRI-Guided radiation boost shows promise in head and neck cancer trial
- New combo drug trial hopes to shrink Hard-to-Treat cancers
- Promising combo therapy for head and neck cancer hits early snag